Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors.[1] It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial.[2][3][4] The drug is a peptide with amino acid sequence YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3.[5]
^Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. (September 2022). "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept". Cell Metabolism. 34 (9): 1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID 35985340. S2CID 251675508.
^"Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight" (Press release). Eli Lilly. 26 June 2023. Retrieved 3 July 2023.
^Constantino, Annika Kim (26 June 2023). "Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients". CNBC. Retrieved 3 July 2023.
^Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. (June 2023). "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial". The New England Journal of Medicine. 389 (6): 514–526. doi:10.1056/NEJMoa2301972. PMID 37366315. S2CID 259260926. Free access subject to registration.
Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple hormone...
to over 1.3 billion. No country is expected to see a decline. 26 June Retatrutide, an experimental drug against obesity, is shown to achieve a more than...
Global Information